Pediatrics

C-Path’s Pediatrics Program unites regulators, pharmaceutical and biotech companies, academics, and patient advocates to advance drug development and create solutions for children living with T1D, Alpha-1 Antitrypsin Deficiency, Lysosomal Diseases, and neonatal complications.

Critical Path for Alpha-1 Antitrypsin Deficiency

Rare and Orphan Diseases Pediatrics

Critical Path for Lysosomal Diseases Pre-Consortium

Rare and Orphan Diseases Pediatrics

Duchenne Regulatory Science Consortium

Neuroscience Rare and Orphan Diseases Pediatrics

International Neonatal Consortium

Polycystic Kidney Disease Outcomes Consortium

Rare and Orphan Diseases Pediatrics

Rare Disease Clinical Outcome Assessment Consortium

Core Competencies Rare and Orphan Diseases Pediatrics Clinical Outcome Assessment

Type 1 Diabetes Consortium

Pediatrics Innovation in Translational Science and Biomarkers